Is Eikon Therapeutics, Inc. (EIKN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 26.1% / 30% | 28.4% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 26.1% / 33% | 28.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 41.2% / 33% | 44.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 26.1% / 33% | 28.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 41.2% / 33% | 44.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$135M |
| Free Cash Flow | -$220M |
| Total Debt | $202M |
| Debt-to-Equity | 85.7 |
| Current Ratio | 8.8 |
| Total Assets | $491M |
Price & Trading
| Last Close | $10.53 |
| 50-Day MA | $13.55 |
| 200-Day MA | $13.55 |
| Avg Volume | 563K |
|
52-Week Range
$9.81
| |
About Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Eikon Therapeutics, Inc. (EIKN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Eikon Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Eikon Therapeutics, Inc.'s debt ratio?
Eikon Therapeutics, Inc.'s debt ratio is 26.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 41.2%.
What are Eikon Therapeutics, Inc.'s key financial metrics?
Eikon Therapeutics, Inc. has a market capitalization of $530M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.